8-K: Tonix Initiates Phase 1 Study for Migraine Drug TNX-1900

Tonix Pharmaceuticals announced the dosing of the first participant in a Phase 1 investigator-initiated study for TNX-1900, its intranasal potentiated oxytocin product candidate, to assess its potential for treating migraine and craniofacial pain.

Summary

• The first participant was dosed in a Phase 1 investigator-initiated study for TNX-1900 (intranasal potentiated oxytocin).
• The study evaluates TNX-1900's effect on trigeminal nerve-mediated vasodilation of the forehead using capsaicin and electrical stimulation, a model for trigeminal neurovascular reactivity, in healthy female human volunteers.
• Dr. Antoinette Maassen van den Brink, Professor of Neurovascular Pharmacology, Erasmus University Medical Center, is the principal investigator for the study.
• TNX-1900 is being developed as a potential non-opioid treatment for migraine, craniofacial pain, and other related conditions, including trigeminal neuralgia.
• In animal studies, intranasal oxytocin has been shown to bind to oxytocin receptors in the trigeminal ganglion, blocking the release of calcitonin gene-related peptide (CGRP), a potent vasodilator involved in migraine pathogenesis.
• The study utilizes Laser Speckle Contrast Imaging (LSCI) for real-time and higher-resolution dermal blood flow measurements.
• Migraine is a neurovascular condition affecting approximately 1.2 billion individuals globally annually, with 39 million Americans suffering, and about 4 million experiencing chronic migraines.
• TNX-1900 is a drug-device combination product designed for targeted intranasal delivery of oxytocin, which concentrates in the trigeminal system.
• The formulation includes magnesium, which enhances oxytocin receptor binding and has inhibitory effects on trigeminal neurons.
• Intranasal oxytocin has been well tolerated in several clinical trials in both adults and children and has no recognized addiction potential.
• Beyond craniofacial pain, TNX-1900 is also being developed for binge eating disorder, adolescent obesity, bone health in pediatric autism, arginine-vasopressin deficiency, and insulin resistance.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating progress in Tonix's pipeline with a potentially differentiated migraine treatment, though it is still very early stage (Phase 1).

Positives

• Initiation of a Phase 1 study for TNX-1900 marks progress in developing a potential new treatment for migraine and craniofacial pain.
• TNX-1900 targets a distinct pathway (oxytocin-mediated CGRP release blockade) compared to existing CGRP inhibitors and triptans, potentially addressing unmet medical needs.
• The product candidate is being developed as a potential non-opioid treatment.
• The study employs Laser Speckle Contrast Imaging (LSCI), a newer detection method providing real-time and higher-resolution dermal blood flow measurements.
• Intranasal delivery of oxytocin aims for targeted action in the trigeminal system, potentially leading to lower systemic exposure and reduced risk of non-nervous system, off-target effects compared to systemic CGRP inhibition.
• Oxytocin has no recognized addiction potential and has been well tolerated in previous clinical trials.
• Daily dosing offers more rapid reversibility compared to monthly or quarterly dosing of anti-CGRP antibodies, providing greater control for physicians and patients.

Risks

• Risks related to the failure to successfully launch and commercialize TONMYA and any approved products.
• Risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.
• Risks related to the timing and progress of clinical development of product candidates.
• Need for additional financing.
• Uncertainties of patent protection and litigation.
• Uncertainties of government or third-party payor reimbursement.
• Limited research and development efforts and dependence upon third parties.
• Substantial competition in the pharmaceutical market.
• Significant inherent risks in the development, regulatory approval, and commercialization of new pharmaceutical products.

Future Outlook

The results of the Phase 1 study will guide future development of TNX-1900 as a potential non-opioid treatment for migraine and other craniofacial pain conditions. The company is also developing TNX-1900 for other indications including binge eating disorder, adolescent obesity, bone health in pediatric autism, arginine-vasopressin deficiency, and insulin resistance.

Management Comments

• "We are excited to collaborate with Professor Maassen van den Brink on this proof-of-concept study investigating the potential for TNX-1900 for treating migraine, craniofacial pain, and other related conditions." Seth Lederman, MD, Chief Executive Officer of Tonix Pharmaceuticals.
• "While there are several CGRP inhibitors approved for the treatment of migraine, TNX-1900’s oxytocin treatment affects a distinct pathway that could address unmet needs. The results of the new study will guide future development of this potential non-opioid treatment for migraine and other craniofacial pain conditions." Seth Lederman, MD, Chief Executive Officer of Tonix Pharmaceuticals.
• "We are excited to be using LSCI in this study of TNX-1900, which adds to our established model by providing real-time and higher resolution dermal blood flow measurements, compared to Laser Doppler Perfusion Imaging used in earlier studies." Dr. Antoinette Maassen van den Brink, Principal Investigator.
• "Oxytocin represents a potential new therapeutic option, targeting a pathway in migraine and craniofacial pain that is distinct from both the triptan and CGRP inhibitor migraine treatment drug classes." Dr. Antoinette Maassen van den Brink, Principal Investigator.

Industry Context

StockSavvy.ai notes that the initiation of a Phase 1 study for TNX-1900 positions Tonix Pharmaceuticals in the competitive migraine and craniofacial pain market. The focus on a distinct oxytocin-mediated pathway for CGRP inhibition differentiates it from established triptans and newer CGRP receptor antagonists/antibodies, potentially offering a novel therapeutic option with a different safety profile, particularly regarding systemic exposure and reversibility.

Comparison to Industry Standards

• TNX-1900's mechanism of blocking CGRP release via oxytocin is distinct from CGRP receptor antagonists (e.g., Ubrelvy, Nurtec ODT) and anti-CGRP antibodies (e.g., Aimovig, Ajovy, Emgality, Vyepti), which either block the receptor or bind to the peptide itself.
• The intranasal delivery aims for targeted action in the trigeminal system, potentially reducing systemic off-target effects that can be associated with systemic CGRP inhibition, which has roles in cardiovascular function.
• Daily dosing of TNX-1900 offers more rapid reversibility compared to the monthly or quarterly dosing schedules of anti-CGRP antibodies.
• The use of Laser Speckle Contrast Imaging (LSCI) in the study represents an advancement over older Laser Doppler Perfusion Imaging for measuring dermal blood flow in neurovascular reactivity models.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if TNX-1900 progresses successfully through clinical trials and gains regulatory approval, offering a novel treatment. However, early-stage clinical trials carry significant risk.
• Patients (Migraine/Craniofacial Pain): Potential for a new, non-opioid treatment option with a distinct mechanism of action and potentially improved safety profile compared to existing therapies.
• Medical Community: Introduction of a novel therapeutic approach (oxytocin-mediated CGRP inhibition) for migraine and craniofacial pain, potentially expanding treatment paradigms.

Next Steps

• The results of the Phase 1 study will guide future development of TNX-1900 for migraine and craniofacial pain conditions.
• Further development of TNX-1900 for other indications including binge eating disorder, adolescent obesity, bone health in pediatric autism, arginine-vasopressin deficiency, and insulin resistance.

Key Dates

Recommendation

The initiation of a Phase 1 study for TNX-1900 is a positive step, demonstrating pipeline progress and a novel approach to migraine treatment. However, it is a very early-stage clinical trial, and the path to market is long, costly, and uncertain. Given the high failure rate of drugs in Phase 1, a "hold" recommendation is appropriate for investors to monitor further clinical data and de-risking events before considering a stronger position.

Keywords

TNX-1900, migraine, craniofacial pain, oxytocin, Phase 1 study, biotechnology, pharmaceuticals, CGRP, trigeminal neuralgia, pain management, clinical trial, neurovascular